D. S. St. Laurent

发表

Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.

L. Hamann, A. Fura, N. Meanwell, 2014, Journal of medicinal chemistry.

HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.

N. Meanwell, J. Lemm, B. Pearce, 2014, Journal of medicinal chemistry.

Effect of a novel thrombin active-site inhibitor on arterial and venous thrombosis.

W. Schumacher, S. Seiler, N. Balasubramanian, 1994, European journal of pharmacology.

Active site-directed synthetic thrombin inhibitors: synthesis, in vitro and in vivo activity profile of BMY 44621 and analogs. An examination of the role of the amino group in the D-Phe-Pro-Arg-H series.

N. Meanwell, W. Schumacher, J. J. Wright, 1993, Journal of Medicinal Chemistry.

Sordarin oxazepine derivatives as potent antifungal agents.

Stella Huang, C. Mazzucco, M. Serrano-Wu, 2002, Bioorganic & medicinal chemistry letters.

Active site-directed thrombin inhibitors--II. Studies related to arginine/guanidine bioisosteres.

N. Meanwell, A. Trehan, J. J. Wright, 1995, Bioorganic & medicinal chemistry.

Discovery of a fluoroindolo[2,3-a]carbazole clinical candidate with broad spectrum antitumor activity in preclinical tumor models superior to the marketed oncology drug, CPT-11.

D. Langley, C. Fairchild, R. Kramer, 2005, Journal of medicinal chemistry.

Inhibitors of HCV NS5A: From Iminothiazolidinones to Symmetrical Stilbenes.

N. Meanwell, M. Deshpande, Scott W. Martin, 2011, ACS medicinal chemistry letters.

Novel 3',6'-anhydro and N12,N13-bridged glycosylated fluoroindolo[2,3-a]carbazoles as topoisomerase I inhibitors. Fluorine as a leaving group from sp3 carbon.

Stella Huang, D. Langley, C. Fairchild, 2005, Organic letters.

HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies.

A. Good, N. Meanwell, J. Lemm, 2013, Bioorganic & medicinal chemistry letters.

Hepatitis C virus NS5A replication complex inhibitors. Part 6: Discovery of a novel and highly potent biarylimidazole chemotype with inhibitory activity toward genotypes 1a and 1b replicons.

A. Good, N. Meanwell, J. Lemm, 2014, Journal of medicinal chemistry.

Sordaricin antifungal agents.

C. Mazzucco, A. Marinier, M. Serrano-Wu, 2003, Bioorganic & medicinal chemistry letters.

Oxime derivatives of sordaricin as potent antifungal agents.

C. Mazzucco, M. Serrano-Wu, J. Barrett, 2002, Bioorganic & medicinal chemistry letters.

Discovery and development of hepatitis C virus NS5A replication complex inhibitors.

N. Meanwell, D. Langley, J. Lemm, 2014, Journal of medicinal chemistry.

HCV NS5A replication complex inhibitors. Part 5: discovery of potent and pan-genotypic glycinamide cap derivatives.

A. Good, N. Meanwell, J. Lemm, 2013, Bioorganic & medicinal chemistry letters.

Identification of Hepatitis C Virus NS5A Inhibitors

N. Meanwell, M. Deshpande, Scott W. Martin, 2009, Journal of Virology.

HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamides.

N. Meanwell, J. Lemm, M. Gao, 2012, Bioorganic & medicinal chemistry letters.